| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73fe06ed0583188da3b5da5250fa30bf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61f88efcda59d7062a4252ecf6886f58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d9d905def314309a500f8b084226696 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16134 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-703
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6804 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867 |
| filingDate |
1999-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07ac5f3d8374d3c4f8098641b87328a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e06894c0f3b59fc1263a24251345006f |
| publicationDate |
1999-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9961596-A2 |
| titleOfInvention |
Novel post-transcriptional regulatory elements and uses thereof |
| abstract |
The invention provides a novel post-transcriptional regulatory element that can function as an RNA nucleo-cytoplasmic transport element. The invention also provides for an attenuated HIV-1 hybrid virus for use as a vaccine and a kit incorporating the hybrid virus. The kit also includes instructional material teaching the use of the vaccine, where the instructional material indicates that the vaccine is used for the prophylaxis or amelioration of HIV-1 infection in a mammal; that the vaccine is to be administered to a mammal in a therapeutically effective amount sufficient to express a viral protein; where the vaccine will not cause clinically significant CD4+ cell depletion; and, the expression of the viral protein elicits an immune response to the attenuated HIV-1 virus. The invention further provides for a method for screening for post-transcriptional RNA nucleo-cytoplasmic transport element (NCTE) binding proteins. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2116605-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2003517839-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004113547-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8163542-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004113547-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8076100-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6656706-B2 |
| priorityDate |
1998-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |